Damiański, P.; Białas, A.J.; Kołacińska-Flont, M.; Elgalal, A.; Jarmakowska, K.; Kierszniewska, D.; Panek, M.; Kardas, G.; Kuna, P.; Kupczyk, M.
Pathway to Remission in Severe Asthma: Clinical Effectiveness and Key Predictors of Success with Benralizumab Therapy: A Real-Life Study. Biomedicines 2025, 13, 887.
https://doi.org/10.3390/biomedicines13040887
AMA Style
Damiański P, Białas AJ, Kołacińska-Flont M, Elgalal A, Jarmakowska K, Kierszniewska D, Panek M, Kardas G, Kuna P, Kupczyk M.
Pathway to Remission in Severe Asthma: Clinical Effectiveness and Key Predictors of Success with Benralizumab Therapy: A Real-Life Study. Biomedicines. 2025; 13(4):887.
https://doi.org/10.3390/biomedicines13040887
Chicago/Turabian Style
Damiański, Piotr, Adam Jerzy Białas, Marta Kołacińska-Flont, Anna Elgalal, Katarzyna Jarmakowska, Dorota Kierszniewska, Michał Panek, Grzegorz Kardas, Piotr Kuna, and Maciej Kupczyk.
2025. "Pathway to Remission in Severe Asthma: Clinical Effectiveness and Key Predictors of Success with Benralizumab Therapy: A Real-Life Study" Biomedicines 13, no. 4: 887.
https://doi.org/10.3390/biomedicines13040887
APA Style
Damiański, P., Białas, A. J., Kołacińska-Flont, M., Elgalal, A., Jarmakowska, K., Kierszniewska, D., Panek, M., Kardas, G., Kuna, P., & Kupczyk, M.
(2025). Pathway to Remission in Severe Asthma: Clinical Effectiveness and Key Predictors of Success with Benralizumab Therapy: A Real-Life Study. Biomedicines, 13(4), 887.
https://doi.org/10.3390/biomedicines13040887
